Instrument Inactif

Communiqués Jaguar Health Inc Nasdaq

Actions

US47010C2017

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Jaguar Health : Corporate Presentation – June 21, 2024	21/06	PU
Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024	13/06	AQ
Jaguar Health : Private Placement Form 8 K	10/06	PU
Nasdaq Stocks Soaring to the Top with Strategic Splits: NVDA, INBS, JAGX, SINT, GWAV	05/06	AQ
Investigator-Initiated Trial of Jaguar Health's Crofelemer Yields Positive Results for Functional Diarrhea	29/05	AQ
Jaguar Health Announces Reverse Stock Split	20/05	AQ
Jaguar Health : Corporate Presentation – May 15, 2024	15/05	PU
Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials and Corporate Updates	09/05	AQ
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion about Microvillus Inclusion Disease	30/04	AQ
Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society Congress in Support of Company's Expanding Focus on Cancer Supportive Care	23/04	AQ
Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care	19/04	AQ
Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders	10/04	AQ
Jaguar Health Granted Extension until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement	09/04	AQ
Jaguar Health : Corporate Presentation – April 1, 2024	05/04	PU
Jaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International	03/04	AQ
Jaguar Health Reports 2023 Financial Results	02/04	AQ
Jaguar Health to Hold Investor Webcast Monday, April 1st at 8:30 AM Eastern Regarding Q4 2023 Financials and Corporate Updates	28/03	AQ
Jaguar Health Requests and Receives Hearing on Nasdaq Listing Compliance	26/02	AQ
Jaguar Health Donates Supply of Mytesi to Humanitarian Aid Organization Direct Relief	15/02	AQ
Jaguar Health Announces Submission of Orphan Drug Designation Application to the FDA for Crofelemer for Cholera-Related Diarrhea	13/02	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Jaguar Health Inc Nasdaq

Actions

US47010C2017

Communiqués

Filtres